Product Pipeline
12/22/2000 Corixa and Coulter complete merger to form comprehensive immunotherapy company
12/21/2000 Corixa and Coulter shareholders approve merger
12/18/2000 Final termination clause expires for proposed Corixa and Coulter merger
12/12/2000 Hart-Scott Rodino waiting period expires for proposed Corixa and Coulter merger
12/04/2000 Coulter Pharmaceutical and Smithkline Beecham announce promising results with Bexxar in NHL patients who previously failed Rituximab treatment
11/27/2000 Corixa and Coulter provide program and operations update on merger
11/14/2000 Coulter Pharmaceutical and SmithKline Beecham announce acceptance of license application for Bexxar
Coulter to receive $5 million equity investment from SmithKline Beecham
11/02/2000 Phase I/II clinical trial results of Corixa's AnergiX.RA complex presented at American College of Rheumatology conference
Corixa's AnergiX.RA complex shows evidence of biological activity and clinical improvement
10/30/2000 Corixa's Melacine melanoma vaccine phase III clinical trial data presented at Society of Biological Therapy meeting
Clinical benefit for Corixa's Melacine melanoma vaccine found to be highest in patients with specific HLA types
10/26/2000 Corixa reports strong third quarter revenues
10/16/2000 Corixa and Coulter merge to create a comprehensive immunotherapy company
Combined company to include late-stage clinical products, dedicated sales and marketing operations and complementary technology platforms
09/29/2000 Corixa receives $2.3 million grant from the National Institute of Allergy and Infectious Diseases to develop tuberculosis vaccine
09/27/2000 Corixa announces its intent to file a Biological License Application with the U.S. Food and Drug Administration on the use of its Melacine vaccine for treatment of stage II melanoma
Preparation of Biological License Application to begin immediately
09/25/2000 Corixa and Purdue Pharma collaborate to discover and develop therapeutic antibodies for cancer
Agreement combines Corixa's antigen discovery expertise with Purdue Pharma's product development and commercialization capabilities
09/07/2000 Corixa appoints James W. Young Ph.D. to its board of directors
Replaces seat vacated by departure of Andrew Senyei, M.D.
08/16/2000 Corixa provides clinical research and product development update at its first annual analyst conference on August 16, 2000
08/15/2000 Medicis and Corixa sign strategic alliance to develop and commercialize Corixa's novel psoriasis product
07/27/2000 Corixa reports second quarter results and provides intellectual property update
Revenue for second quarter of 2000 up 21 percent from second quarter of 1999
07/26/2000 Coulter Pharmaceutical and SmithKline Beecham expand proprietary position with second U.S. patent grant this year
07/26/2000 Coulter Pharmaceutical and SmithKline Beecham initiate clinical trial of Bexxar in combination with chemotherapy to treat intermediate-grade NHL
Coulter to receive milestone payment from SB
06/07/2000 Corixa and Medarex form alliance to discover and develop therapeutic monoclonal antibodies
Multi-product collaboration to target autoimmune diseases, cancer and infectious diseases
05/05/2000 Corixa announces the exercise of over-allotment option for the purchase of 100,000 shares of common stock
04/26/2000 Corixa reports strong first quarter results
Revenue for first quarter increased 184 percent compared to prior year period
04/26/2000 Coulter Pharmaceutical and SmithKline Beecham combine Bexxar with CVP chemotherapy in a new first-line clinical trial
04/17/2000 Corixa receives $1 million milestone payment from Organon as part of rheumatoid arthritis treatment collaboration
Randomized, blinded, placebo-controlled, phase I/II dose escalation trial completed
04/11/2000 Corixa receives U.S. patent on AnervaX.RA vaccine for the treatment of rheumatoid arthritis
04/07/2000 Corixa announces the sale of 1,900,000 shares of common stock in a follow-on public stock offering
04/05/2000 Coulter Pharmaceutical announces preferential tumor activation and tumor inhibition with prodrug CPI-0004
03/27/2000 Corixa and Wyeth Lederle Vaccines expand alliance
Expanded agreement adds new MPL adjuvant formulation and new disease field rights
03/23/2000 Infectious Disease Research Institute Receives $15 million donation from the Bill & Melinda Gates Foundation
Effort to target clinical development of Corixa’s leishmaniasis vaccine
03/21/2000 Corixa and Abgenix form alliance to discover and develop therapeutic monoclonal antibodies
Corixa and Abgenix form alliance to discover and develop therapeutic monoclonal antibodies
Multi-product collaboration to target autoimmune diseases, cancer and infectious diseases
03/07/2000 Corixa files registration statement for follow-on public offering of 2,250,000 shares of common stock
03/03/2000 Corixa and QLT announce multi-year collaboration
New agreement would combine photodynamic therapy and immunotherapy to treat multiple disease areas
02/22/2000 Corixa reports fourth quarter and year end results
Year end revenue increased 45 percent compared to 1998
02/18/2000 Data on Corixa's Melacine presented at melanoma conference
Analysis of phase III trial provides evidence of safety and potential clinical activity
02/09/2000 Incyte and Corixa enter into a genomic partnership for vaccine discovery through access to LifeSeq Gold
02/08/2000 Corixa and Genset collaborate to sequence microbial genome
02/02/2000 Coulter Pharmaceutical and SmithKline Beecham announce U.S. patent on radioimmunotherapy for B-cell lymphomas
01/11/2000 Corixa receives FDA clearance to initiate phase II PVAC clinical trials
Phase II U.S. trial of Corixa’s psoriasis treatment expected to begin in January 2000
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Current and archived company press releases.